Tesofensine – a novel potent weight loss medicine

  title={Tesofensine – a novel potent weight loss medicine},
  author={Sheila Anne Doggrell},
  journal={Expert Opinion on Investigational Drugs},
  pages={1043 - 1046}
  • S. Doggrell
  • Published 24 June 2009
  • Medicine
  • Expert Opinion on Investigational Drugs
Background: The incidence of obesity is increasing; this is of major concern, as obesity is associated with cardiovascular disease, stroke, type 2 diabetes, respiratory tract disease, and cancer. Objectives/methods: This evaluation is of a Phase II clinical trial with tesofensine in obese subjects. Results: After 26 weeks, tesofensine caused a significant weight loss, and may have a higher maximal ability to reduce weight than the presently available anti-obesity agents. However, tesofensine… 
New and Emerging Drug Molecules Against Obesity
This review is an attempt to describe the new and emerging molecules that are in clinical development for obesity.
Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon
Though there are approved anti-obesity drugs available in the USA, newer drugs are now in the pipeline for development given the urgent need, with potential to vastly expand allowing better treatment options and personalized approach to obesity care.
The unrelenting fall of the pharmacological treatment of obesity
This review aims at revising the failed promises of antiobesity drugs and describing the few potential future candidates in order to shed some light in the still uncertain field of antiOBesity drugs.
Serotonergic Anti-Obesity Agents
Evidence indicates that tesofensine strengthens satiety, but behavioural specificity and psychological side effects remain an issue, and the serotonergic system remains a viable target for anti-obesity treatment.
Anti‐hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats
The sympathomimetic mode of action of tesofensine may also associate with the elevated heart rate and blood pressure observed in clinical settings, and this work sought experimentally to address this issue.
Pharmacological management of appetite expression in obesity
Behavioral analysis can identify drugs that selectively affect desire to eat, enjoyment of eating, satiation or postmeal satiety, and rational interventions designed specifically to modulate these processes could limit the normally aversive consequences of caloric restriction and maximize an individual's capacity to successfully gain control over their appetite.
Pharmacological Interventions for Obesity: Current and Future Targets
  • M. Bocarsly
  • Biology, Medicine
    Current Addiction Reports
  • 2018
Purpose of ReviewObesity in the USA has been on a constant rise since the Center for Disease Control and Prevention (CDC) began tracking it over 50 years ago. Despite focused attention on this
Effect of Anti-Obesity Drug on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
It was identified that anti-obesity therapy was associated with a decrease of weight regardless of the type of the drug, and Sibutramine may have a direct effect on cardiovascular risk factors.
Medical Weight Management
The goals of medical weight management should be to reduce central abdominal fat stores, to prevent, eliminate, or improve obesity-related complications, to improve quality of life, and to reduce mortality in the obese and overweight populations with comorbidities.
Identification of key candidate genes and molecular pathways in white fat browning: an anti-obesity drug discovery based on computational biology
Drug discovery using in silico text mining, pathway, and protein-protein interaction analysis tools may be a method of exploring drugs targeting the activation of brown fat or white fat browning, which provides a basis for the development of novel targeted therapies as potential treatments for obesity and related metabolic diseases.


Is rimonabant efficacious and safe in the treatment of obesity?
  • S. Doggrell
  • Medicine
    Expert opinion on pharmacotherapy
  • 2008
Unless rimonabant is shown to have benefits in ongoing clinical outcome studies, there is little rationale to support its use in the treatment of obesity.
An assessment of the safety and efficacy of sibutramine, an anti‐obesity drug with a novel mechanism of action
  • E. Nisoli, M. Carruba
  • Medicine
    Obesity reviews : an official journal of the International Association for the Study of Obesity
  • 2000
Successful treatment of moderately hypertensive obese patients with sibutramine has been demonstrated without undue blood pressure problems and even a mean lowering of blood pressure associated with weight loss, and it is indistinguishable from placebo in abuse potential studies.
Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic‐pharmacodynamic modelling approach
A thorough characterization of the pharmacokinetic (PK) properties of tesofensine and M1 in mice is accomplished and the potency and concentration‐time course of the active metabolite M1 relative to tes ofensine are evaluated using the PK/PD modelling approach.
Effect of orlistat on cardiovascular disease risk in obese adults
Comparing the effect of orlistat vs. placebo on the predicted 10‐year cardiovascular disease (CVD) risk in obese people with one or more cardiovascular risk factors treated for 12 months in conjunction with a fat‐reduced, but otherwise ad libitum, diet is compared.
Weight Loss Produced by Tesofensine in Patients With Parkinson's or Alzheimer's Disease
A meta‐analysis of TE's effect on body weight in trials investigating its potential for treatment of Parkinson's or Alzheimer's disease was conducted.
Obesity in Adulthood and Its Consequences for Life Expectancy: A Life-Table Analysis
An estimate of the effect of obesity and overweight in adulthood on life expectancy is provided, implicitly taking into account the various possible weight trajectories throughout the life course, based on data from the Framingham Heart Study.
NS-2330 (Neurosearch).
  • U. Thatte
  • Psychology
    Current opinion in investigational drugs
  • 2001
NeuroSearch is developing NS-2330, a compound that increases the activity of dopamine, norepinephrine and acetylcholine, as a potential therapy for Alzheimer's disease (AD) and Parkinson's disease